Holding(s) in Company

RNS Number : 1308R

Hikma Pharmaceuticals Plc

25 June 2020

 

TR-1: S tandard form for notification of major holdings

LONDON, 25 June 2020 - Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) (LSE: HIK) announces as follows:

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :			Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75)
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligation iv
Name			Boehringer Ingelheim Invest GmbH
City and country of registered office (if applicable)			Ingelheim am Rhein, Germany
4. Full name of shareholder(s) (if different from 3.) v
Name			N/A
City and country of registered office (if applicable)			N/A
5. Date on which the threshold was crossed or reached vi :			23 June 2020 25 June 2020
6. Date on which issuer notified (DD/MM/YYYY):			25 June 2020
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached	23 June 2020: 12,833,233  shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%.	0		23 June 2020: 12,833,233  shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%.	23 June 2020: 12,833,233  shares bought back by the issuer with a resultant position of 27,166,767. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0.
Position of previous notification (if applicable)	16.67%	0		16.67%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary shares of 10 pence each (GB00B0LCW083)		23 June 2020: 12,833,233  shares bought back by the issuer with a resultant position of 27,166,767 . 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0.		0			23 June 2020: 12,833,233  shares bought back by the issuer with a resultant position of 11.16%. 25 June 2020: Remaining 27,166,767 shares sold in a placing with a resultant position of 0%.		0
SUBTOTAL 8. A		23 June 2020: 27,166,767 25 June 2020: 0					23 June 2020: 11.16% 25 June 2020: 0%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
N/A
			SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash settlement xii			Number of voting rights	% of voting rights
N/A
					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)				X
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
C.H. Boehringer Sohn AG & Co. KG	0	0	0
Boehringer Ingelheim Corporate Center GmbH	0	0	0
Boehringer Ingelheim Verwaltungs GmbH	0	0	0
Boehringer Ingelheim International GmbH	0	0	0
Boehringer Ingelheim Auslandsbeteiligungs GmbH	0	0	0
10. In case of proxy voting, please identify:
Name of the proxy holder		N/A
The number and % of voting rights held		N/A
The date until which the voting rights will be held		N/A
11. Additional information xvi
None

Place of completion	Germany
Date of completion	Buyback by the issuer completed 23 June 2020. Sale in the placing completed 25 June 2020.

 

END

 

 

HOLUVAVRRRUNUAR